Irenotecan (CPT-11): Recent developments and future directions - Colorectal cancer and beyond

Oncologist

Volumn 6, Issue 1, 2001, Pages 66-80

  Rothenberg, Mace L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; CPT 11; Irinotecan; Review; Topoisomerase

Indexed keywords

ACETORPHAN; CISPLATIN; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 15; IRINOTECAN; JBT 3002; LOPERAMIDE; THROMBOXANE A2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG COMBINATION; GASTROINTESTINAL TUMOR; LUNG TUMOR; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS;

EID: 0034746224     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-1-66     Document Type: Review

References (99)

1. In vitro activation of irinotecan to SN-38 by human liver and intestine
2. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
3. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA
4. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
5. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
6. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
7. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
8. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
9. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
10. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
11. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo
12. Sequence-dependent activity of the irinotecan-5-FU combination in human colon-cancer model HT-29 in vitro and in vivo
13. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity
14. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose
15. Assessment of the efficacy of the irinotecan (CPT-11)-5-fluorouracil (5-FU) combination in a panel of colon carcinoma cell lines
16. Effects of CPT-11 in combination with other anti-cancer agents in culture
17. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
18. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N6-ethenoadenine
19. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
20. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell from the National Cancer Institute anticancer screen
21. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
22. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance
23. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors
24. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I
25. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
26. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin
27. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel antitumor agent, by carboxylesterase
28. Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
29. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
30. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment
31. Gastrointestinal toxicity of irinotecan
32. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
33. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of FDA-reviewed pivotal US clinical trials
34. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
35. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
36. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium
37. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
38. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
39. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
40. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
41. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
42. First-line irinotecan, fluorouracil, leucovorin especially improves survival in metastatic colorectal cancer patients with favorable prognostic indicators
43. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
44. Thymidylate synthase as a predictor of response
45. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers
46. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer
47. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
48. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
49. Phase II study of CPT-11 and cisplatin in patients with advanced gastric carcinoma
50. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas
51. Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer
52. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
53. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer
54. Multicenter phase II trial of first-line irinotecan and gemcitabine (irimogem) in patients with locally advanced or metastatic pancreatic cancer (PC)
55. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small cell lung cancer CPT-11 Lung Cancer Study Group
56. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
57. Randomized multicenter Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer
58. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
59. Preliminary results of a multicenter Phase II trial of weekly cisplatin (CDDP) and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC): A Vanderbilt Cancer Center Affiliate Network study
60. Phase I/II trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11), in advanced or metastatic non-small cell lung cancer (NSCLC)
61. Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer
62. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
63. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts
64. DNA topoisomerase I-targeting drags as radiation sensitizers
65. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
66. Phase I trial of out-patient weekly irinotecan and concurrent radiation therapy for stage III unresectable non-small cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial
67. A phase I study of irinotecan (CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC)
68. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC)
69. Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): A phase II study Japan Clinical Oncology Group (JCOG9504)
70. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer
71. A Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in previously treated small cell lung cancer (SCLC)
72. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group
73. Phase II and pharmacokinetic (PK)/pharmacodynamic (PD) study of carboplatin (CBDCA) and irinotecan (CPT-11) in patients with small cell lung cancer (SCLC)
74. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small cell lung cancer (ED-SCLC): A study of the West Japan Lung Cancer Group
75. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511)
76. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer
77. Phase I study of the combination of irinotecan (CPT-11) and paclitaxel (Taxol) in previously treated patients (pts) with small cell carcinoma of the lung (SCCL)
78. Phase I/II trial of weekly cisplatin (DDP), etoposide (ETOP) and irinotecan (CPT) for metastatic lung cancer (JCOG Study 9507)
79. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot phase II clinical trial and pharmacokinetic profile
80. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
81. Irinotecan (CPT-11) in chemotherapy naïve (CN) patients (Pts) with glioblasroma (GB): Final results of a multicenter phase II study with pharmacokinetic analysis
82. Anticonvulsants alter the pharmacokinetics of irinotecan (CPT-11) in patients with recurrent glioma
83. Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: Results of an NCCTG phase II trial
84. Irinotecan treatment for recurrent malignant glioma using an every three week regimen
85. Intrapatient dose escalation of irinotecan in patients with recurrent malignant glioma receiving anticonvulsants
86. Topoisomerase I inhibitors: Review and update
87. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
88. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A gynecologic oncology group study
89. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
90. Results of a European Organization for Research and Treatment of Cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
91. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
92. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer
93. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer
94. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: Doxorubicin, cisplatin, irinotecan or topotecan
95. Phase II trial of irinotecan (CPT-11) in metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
96. Phase II study of irinotecan (CPT-11) in patients with previously treated small cell lung cancer (SCLC)
97. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC)
98. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
99. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer